{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:03:52Z","timestamp":1783937032235,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["P50 DE026787"],"award-info":[{"award-number":["P50 DE026787"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000124","name":"Office of Research on Women's Health","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11864-022-00945-5","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T10:04:59Z","timestamp":1647597899000},"page":"594-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advances in Organ Preservation for Laryngeal Cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Graham","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A","family":"Glazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J","family":"Kimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-7430","authenticated-orcid":false,"given":"Justine Yang","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"1","key":"945_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: Cancer J Clin. 2021Jan 1;71(1):7\u201333.","journal-title":"CA: Cancer J Clin."},{"issue":"24","key":"945_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","volume":"324","author":"GT Wolf","year":"1991","unstructured":"Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991Jun 13;324(24):1685\u201390.","journal-title":"N Engl J Med."},{"issue":"7","key":"945_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. JCO. 2013Mar 1;31(7):845\u201352.","journal-title":"JCO."},{"issue":"1","key":"945_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010Jan 1;11(1):21\u20138.","journal-title":"Lancet Oncol."},{"key":"945_CR5","doi-asserted-by":"crossref","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet. 2019Jan 5;393(10166):40\u201350.","DOI":"10.1016\/S0140-6736(18)32779-X"},{"issue":"27","key":"945_CR6","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, el-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III Trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. JCO. 2014Sep 20;32(27):2940\u201350.","journal-title":"JCO."},{"issue":"4","key":"945_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0360-3016(00)01441-3","volume":"49","author":"KSC Chao","year":"2001","unstructured":"Chao KSC, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001Mar 15;49(4):907\u201316.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"945_CR8","doi-asserted-by":"crossref","unstructured":"Leeman JE, Romesser PB, Zhou Y, McBride S, Riaz N, Sherman E, Cohen MA, Cahlon O, Lee N. Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol. 2017May;18(5):e254\u201365.","DOI":"10.1016\/S1470-2045(17)30179-1"},{"key":"945_CR9","doi-asserted-by":"publisher","first-page":"104879","DOI":"10.1016\/j.oraloncology.2020.104879","volume":"110","author":"X Li","year":"2020","unstructured":"Li X, Lee A, Cohen MA, Sherman EJ, Lee NY. Past, present and future of proton therapy for head and neck cancer. Oral Oncol. 2020Nov 1;110:104879.","journal-title":"Oral Oncol."},{"issue":"1","key":"945_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijrobp.2019.03.011","volume":"105","author":"B-H Kang","year":"2019","unstructured":"Kang B-H, Yu T, Kim JH, Park JM, Kim J-I, Chung E-J, Kwon SK, Kim JH, Wu HG. Early closure of a phase 1 clinical trial for SABR in early-stage glottic cancer. Int J Radiat Oncol Biol Phys. 2019Sep 1;105(1):104\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9388","key":"945_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","volume":"362","author":"J Overgaard","year":"2003","unstructured":"Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. The Lancet. 2003Sep 20;362(9388):933\u201340.","journal-title":"The Lancet."},{"issue":"25","key":"945_CR12","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","volume":"338","author":"DM Brizel","year":"1998","unstructured":"Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998Jun 18;338(25):1798\u2013804.","journal-title":"N Engl J Med."},{"key":"945_CR13","doi-asserted-by":"crossref","unstructured":"Bourhis J, Sire C, Graff P, Gr\u00e9goire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012Feb;13(2):145\u201353.","DOI":"10.1016\/S1470-2045(11)70346-1"},{"issue":"34","key":"945_CR14","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","volume":"32","author":"PF Nguyen-Tan","year":"2014","unstructured":"Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014Dec 1;32(34):3858\u201366.","journal-title":"J Clin Oncol."},{"key":"945_CR15","doi-asserted-by":"crossref","unstructured":"Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006Sep;116(9 Pt 2 Suppl 111):1\u201313.","DOI":"10.1097\/01.mlg.0000236095.97947.26"},{"issue":"21","key":"945_CR16","first-page":"5113","volume":"53","author":"WK Hong","year":"1993","unstructured":"Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993Nov 1;53(21):5113\u201320.","journal-title":"Cancer Res."},{"issue":"4","key":"945_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","volume":"24","author":"S Urba","year":"2006","unstructured":"Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N, Taylor J. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. JCO. 2006Feb 1;24(4):593\u20138.","journal-title":"JCO."},{"key":"945_CR18","doi-asserted-by":"crossref","unstructured":"Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 docetaxel for larynx preservation. J Natl Cancer Inst. 2016Apr;108(4):djv368.","DOI":"10.1093\/jnci\/djv368"},{"key":"945_CR19","doi-asserted-by":"crossref","unstructured":"Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR, TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011Feb;12(2):153\u20139.","DOI":"10.1016\/S1470-2045(10)70279-5"},{"issue":"17","key":"945_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007Oct 25;357(17):1695\u2013704.","journal-title":"N Engl J Med."},{"key":"945_CR21","doi-asserted-by":"crossref","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Galloway T, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020Jul;18(7):873\u201398.","DOI":"10.6004\/jnccn.2020.0031"},{"issue":"22","key":"945_CR22","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003Nov 27;349(22):2091\u20138.","journal-title":"N Engl J Med."},{"issue":"14","key":"945_CR23","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","volume":"21","author":"J Mendelsohn","year":"2003","unstructured":"Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. JCO. 2003Jul 15;21(14):2787\u201399.","journal-title":"JCO."},{"key":"945_CR24","doi-asserted-by":"crossref","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005May;5(5):341\u201354.","DOI":"10.1038\/nrc1609"},{"issue":"2","key":"945_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0360-3016(00)01488-7","volume":"49","author":"PM Harari","year":"2001","unstructured":"Harari PM, Huang S-M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001Feb 1;49(2):427\u201333.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"945_CR26","first-page":"2166","volume":"6","author":"S-M Huang","year":"2000","unstructured":"Huang S-M, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000Jun 1;6(6):2166\u201374.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"945_CR27","first-page":"1935","volume":"59","author":"SM Huang","year":"1999","unstructured":"Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999Apr 15;59(8):1935\u201340.","journal-title":"Cancer Res."},{"issue":"10212","key":"945_CR28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019Nov 23;394(10212):1915\u201328.","journal-title":"The Lancet."},{"key":"945_CR29","doi-asserted-by":"crossref","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PMH, Lin JC, Razaq MA, Teixeira MM, L\u00f6vey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, de Beukelaer S, Pavlov D, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021Apr;22(4):450\u201362.","DOI":"10.1016\/S1470-2045(20)30737-3"},{"key":"945_CR30","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017Nov 16;377(20):1919\u201329.","DOI":"10.1056\/NEJMoa1709937"},{"key":"945_CR31","doi-asserted-by":"crossref","unstructured":"Chen AM, Chen LM, Vaughan A, Farwell DG, Luu Q, Purdy JA, et al. Head and neck cancer among lifelong never-smokers and ever-smokers: matched-pair analysis of outcomes after radiation therapy. Am J Clin Oncol [Internet]. 2011;34(3) Available from: https:\/\/journals.lww.com\/amjclinicaloncology\/Fulltext\/2011\/06000\/Head_and_Neck_Cancer_Among_Lifelong_Never_Smokers.11.aspx","DOI":"10.1097\/COC.0b013e3181dea40b"},{"issue":"8","key":"945_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10654-011-9612-3","volume":"26","author":"N Nicolotti","year":"2011","unstructured":"Nicolotti N, Chuang S-C, Cadoni G, Arzani D, Petrelli L, Bosetti C, Brenner H, Hosono S, la Vecchia C, Talamini R, Matsuo K, M\u00fcller H, Muscat J, Paludetti G, Ricciardi G, Boffetta P, Hashibe M, Boccia S. Recreational physical activity and risk of head and neck cancer: a pooled analysis within the international head and neck cancer epidemiology (INHANCE) Consortium. Eur J Epidemiol. 2011Aug 13;26(8):619\u201328.","journal-title":"Eur J Epidemiol."},{"key":"945_CR33","doi-asserted-by":"crossref","unstructured":"Nocini R, Sanchis-Gomar F, Lippi G. Physical activity and laryngeal cancer. Ann Transl Med. 2019Dec;7(23):791.","DOI":"10.21037\/atm.2019.11.65"},{"issue":"5","key":"945_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.ijrobp.2009.04.011","volume":"76","author":"A Eisbruch","year":"2010","unstructured":"Eisbruch A, Harris J, Garden AS, Chao CKS, Straube W, Harari PM, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010Apr 1;76(5):1333\u20138.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"945_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.radonc.2016.05.022","volume":"120","author":"P Blanchard","year":"2016","unstructured":"Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed ASR, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer \u2013 a case matched analysis. Radiother Oncol. 2016Jul 1;120(1):48\u201355.","journal-title":"Radiother Oncol."},{"issue":"24","key":"945_CR36","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2004.09.959","volume":"22","author":"WM Mendenhall","year":"2004","unstructured":"Mendenhall WM. Mandibular osteoradionecrosis. JCO. 2004Dec 15;22(24):4867\u20138.","journal-title":"JCO."},{"key":"945_CR37","doi-asserted-by":"crossref","unstructured":"Mohamed ASR, Hobbs BP, Hutcheson KA, Murri MS, Garg N, Song J, Brandon Gunn G, Sandulache V, Beadle BM, Phan J, Morrison WH, Frank SJ, Blanchard P, Garden AS, el-Halawani H, Kamal M, Chambers MS, Lewin JS, Ferrarotto R, et al. Dose-volume correlates of mandibular osteoradionecrosis in oropharynx cancer patients receiving intensity-modulated radiotherapy: results from a case-matched comparison. Radiother Oncol. 2017Aug 1;124(2):232\u20139.","DOI":"10.1016\/j.radonc.2017.06.026"},{"key":"945_CR38","doi-asserted-by":"crossref","unstructured":"Heft Neal ME, Smith JD, Birkeland AC, Haring CT, Chinn SB, Shuman AG, Casper KA, Malloy KM, Stucken CL, Mclean SA, Rosko AJ, Mierzwa ML, Shah J, Schonewolf C, Swiecicki PL, Worden FP, Wolf GT, Bradford CR, Prince MEP, et al. Tumor-infiltrating lymphocytes in patients with advanced laryngeal cancer undergoing bioselection. Otolaryngol Head Neck Surg. 2021May;25:01945998211013765.","DOI":"10.1177\/01945998211013765"},{"key":"945_CR39","doi-asserted-by":"crossref","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus\u2013unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020Oct 1;26(19):5140\u201352.","DOI":"10.1158\/1078-0432.CCR-20-1695"},{"key":"945_CR40","doi-asserted-by":"crossref","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen Y-H, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020Oct 1;6(10):1563\u201370.","DOI":"10.1001\/jamaoncol.2020.2955"},{"issue":"4","key":"945_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours. Br J Cancer. 2021Aug 1;125(4):510\u20139.","journal-title":"Br J Cancer."},{"issue":"4","key":"945_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","volume":"125","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer. 2021Aug 1;125(4):520\u20137.","journal-title":"Br J Cancer."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-022-00945-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:28:09Z","timestamp":1649330889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-022-00945-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s11864-022-00945-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"30 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Campbell has no financial disclosures. Dr. Glazer has a leadership role in the AAO-HSN Head and Neck Education Committee. Dr. Kimple has a grant from the National Institute of Health and received personal fees from Guidepoint Global, Mele Associates, and Galera Therapeutics. Dr. Bruce is an advisory board member to Phoenix Solutions, Ideaya Biosciences, Istari Oncology, Lilly, Merck, OncLive, and Sanofi Genzyme. She is a member of the safety monitoring committee for Kura Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}